{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:22:09Z","timestamp":1764174129826,"version":"3.41.2"},"reference-count":52,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T00:00:00Z","timestamp":1480464000000},"content-version":"vor","delay-in-days":760,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":304,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["aip.org"],"crossmark-restriction":true},"short-container-title":["Medical Physics"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:sec><jats:title>Purpose:<\/jats:title><jats:p>Throughout the years, the palliative treatment of bone metastases using bone seeking radiotracers has been part of the therapeutic resources used in oncology, but the choice of which bone seeking agent to use is not consensual across sites and limited data are available comparing the characteristics of each radioisotope. Computational simulation is a simple and practical method to study and to compare a variety of radioisotopes for different medical applications, including the palliative treatment of bone metastases. This study aims to evaluate and compare 11 different radioisotopes currently in use or under research for the palliative treatment of bone metastases using computational methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Computational models were used to estimate the percentage of deoxyribonucleic acid (DNA) damage (fast Monte Carlo damage algorithm), the probability of correct DNA repair (Monte Carlo excision repair algorithm), and the radiation\u2010induced cellular effects (virtual cell radiobiology algorithm) post\u2010irradiation with selected particles emitted by phosphorus\u201032 (<jats:sup>32<\/jats:sup>P), strontium\u201089 (<jats:sup>89<\/jats:sup>Sr), yttrium\u201090 (<jats:sup>90<\/jats:sup>Y), tin\u2010117 (<jats:sup>117m<\/jats:sup>Sn), samarium\u2010153 (<jats:sup>153<\/jats:sup>Sm), holmium\u2010166 (<jats:sup>166<\/jats:sup>Ho), thulium\u2010170 (<jats:sup>170<\/jats:sup>Tm), lutetium\u2010177 (<jats:sup>177<\/jats:sup>Lu), rhenium\u2010186 (<jats:sup>186<\/jats:sup>Re), rhenium\u2010188 (<jats:sup>188<\/jats:sup>Re), and radium\u2010223 (<jats:sup>223<\/jats:sup>Ra).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p><jats:sup>223<\/jats:sup>Ra alpha particles, <jats:sup>177<\/jats:sup>Lu beta minus particles, and <jats:sup>170<\/jats:sup>Tm beta minus particles induced the highest cell death of all investigated particles and radioisotopes. The cell survival fraction measured post\u2010irradiation with beta minus particles emitted by <jats:sup>89<\/jats:sup>Sr and <jats:sup>153<\/jats:sup>Sm, two of the most frequently used radionuclides in the palliative treatment of bone metastases in clinical routine practice, was higher than <jats:sup>177<\/jats:sup>Lu beta minus particles and <jats:sup>223<\/jats:sup>Ra alpha particles.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p><jats:sup>223<\/jats:sup>Ra and <jats:sup>177<\/jats:sup>Lu hold the highest potential for palliative treatment of bone metastases of all radioisotopes compared in this study. Data reported here may prompt future <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> experiments comparing different radionuclides for palliative treatment of bone metastases, raise the need for the careful rethinking of the current widespread clinical use of <jats:sup>89<\/jats:sup>Sr and <jats:sup>153<\/jats:sup>Sm, and perhaps strengthen the use of <jats:sup>223<\/jats:sup>Ra and <jats:sup>177<\/jats:sup>Lu in the palliative treatment of bone metastases.<\/jats:p><\/jats:sec>","DOI":"10.1118\/1.4897240","type":"journal-article","created":{"date-parts":[[2014,10,24]],"date-time":"2014-10-24T00:32:15Z","timestamp":1414110735000},"update-policy":"https:\/\/doi.org\/10.1063\/aip-crossmark-policy-page","source":"Crossref","is-referenced-by-count":22,"title":["Comparative analysis of 11 different radioisotopes for palliative treatment of bone metastases by computational methods"],"prefix":"10.1002","volume":"41","author":[{"given":"Francisco D. C.","family":"Guerra Liberal","sequence":"first","affiliation":[]},{"given":"Adriana Alexandre S.","family":"Tavares","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o Manuel R. S.","family":"Tavares","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2016,11,30]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"B. W.StewartandC. P.Wild World Cancer Report 2014 edited byB. W.StewartandC. P.Wild(IARC Nonserial Publication Lyon 2014) p.630."},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2008.02.061"},{"issue":"4","key":"e_1_2_6_4_1","first-page":"71","article-title":"Radionuclide therapy with bone seeking radionuclides in palliation of painful bone metastases","volume":"22","author":"Maini C. L.","year":"2003","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/719394"},{"issue":"1","key":"e_1_2_6_6_1","first-page":"38S","article-title":"Bone\u2010seeking radionuclides for therapy","volume":"46","author":"Lewington V. J.","year":"2005","journal-title":"J. Nucl. Med."},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.112482"},{"key":"e_1_2_6_8_1","first-page":"249","article-title":"Dosage and Response in radiopharmaceutical therapy of painful osseous metastases dosage and response in radiopharmaceutical therapy of","volume":"37","author":"Silberstein E. B.","year":"1996","journal-title":"J. Nucl. Med."},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0969\u20108043(03)00158\u20101"},{"issue":"4","key":"e_1_2_6_10_1","first-page":"229","article-title":"Production of 177 Lu and formulation of ethylene diamine tetramethylene phosphonate (EDTMP) kits as a bone\u2010seeking radiopharmaceutical","volume":"7","author":"Daha F. J.","year":"2010","journal-title":"Iran. J. Radiat. Res."},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/541487"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S25537"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.3109\/09553000903564083"},{"issue":"2","key":"e_1_2_6_14_1","first-page":"252","article-title":"Targeting of osseous sites with alpha\u2010emitting 223Ra: comparison witn the beta\u2010emitter 89Sr in Mice","volume":"44","author":"Henriksen G.","year":"2003","journal-title":"J. Nucl. Med."},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/cr9804386"},{"issue":"10","key":"e_1_2_6_16_1","first-page":"3207","article-title":"radiopharmaceutical therapy","volume":"57","author":"Ramdahl T.","year":"2013","journal-title":"Phys. Med. Biol."},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2012.07.002"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/290750"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/107327481201900208"},{"issue":"04","key":"e_1_2_6_20_1","first-page":"26","article-title":"Radiopharmaceuticals for cancer therapy","volume":"44","author":"Sivaprasad N.","year":"2012","journal-title":"Pharma times"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2011.12.015"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2012.02.001"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmp.2010.08.001"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.5603\/NMR.2011.00023"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2010.09.013"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2009.09.004"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2009.02.002"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnmt.108.054700"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(07)70147\u2010X"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2004.07.008"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201004\u20102244"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10967\u2010005\u20100920\u20105"},{"issue":"10","key":"e_1_2_6_33_1","first-page":"S3","article-title":"Overview of samarium sm 153 lexidronam in the treatment of painful metastatic bone disease","volume":"6","author":"Sartor O.","year":"2004","journal-title":"Rev. Urol."},{"key":"e_1_2_6_34_1","first-page":"1","article-title":"Table of radionuclides","volume":"1","author":"B\u00e9 M.","year":"2008","journal-title":"Bur. Int. Poids. Mes."},{"issue":"4","key":"e_1_2_6_35_1","first-page":"682","article-title":"Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions","volume":"41","author":"Bouchet L. G.","year":"2000","journal-title":"J. Nucl. Med."},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2012.04.001"},{"issue":"1","key":"e_1_2_6_37_1","first-page":"61","article-title":"Treatment of metastatic bone pain with tin\u2010117m stannic diethylenetriaminepentaacetic acid: A phase I\/II clinical study","volume":"4","author":"Srivastava S. C.","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2005.03.003"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1989.223"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2013.06.004"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1667\/RR3140"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1667\/RR1046.1"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/095530098142176"},{"issue":"1","key":"e_1_2_6_44_1","first-page":"3","article-title":"Radiation track and DNA damage","volume":"1","author":"Nikjoo H.","year":"2003","journal-title":"Iran. J. Radiat. Res."},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1088\/0031\u20109155\/51\/7\/004"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1667\/RR3414"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/095530097143149"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1088\/0031\u20109155\/47\/17\/310"},{"key":"e_1_2_6_49_1","unstructured":"See supplementary material athttp:\/\/dx.doi.org\/10.1118\/1.4897240E\u2010MPHYA6\u201041\u2010007411for the summary of the key clinical outcomes of different radiotracers currently used in the clinical setting or under research for palliative treatment of bone metastases."},{"issue":"5","key":"e_1_2_6_50_1","first-page":"473","article-title":"Implication of cell kinetic changes during the progression of human prostatic cancer","volume":"1","author":"Berges R. R.","year":"1995","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1118\/1.3451117"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1667\/RR3402"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1667\/0033\u20107587(2001)156[0365:TLKMOD]2.0.CO;2"}],"container-title":["Medical Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1118%2F1.4897240","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1118%2F1.4897240","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/aapm.onlinelibrary.wiley.com\/doi\/pdf\/10.1118\/1.4897240","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T10:18:24Z","timestamp":1696587504000},"score":1,"resource":{"primary":{"URL":"https:\/\/aapm.onlinelibrary.wiley.com\/doi\/10.1118\/1.4897240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.1118\/1.4897240"],"URL":"https:\/\/doi.org\/10.1118\/1.4897240","archive":["Portico"],"relation":{},"ISSN":["0094-2405","2473-4209"],"issn-type":[{"type":"print","value":"0094-2405"},{"type":"electronic","value":"2473-4209"}],"subject":[],"published":{"date-parts":[[2014,11]]},"article-number":"114101"}}